

1FW 1615

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Giblin et al.

Docket No.

P33027USW

Serial No.

10/508,761

Filing Date


September 22, 2004

Examiner

Group Art Unit

1615

Invention: (2-(2-Alkoxy)-Phenyl)-Cyclopent-1-Enyl) Aromatic Carbo and Heterocyclic Acid and Derivatives



I hereby certify that this Supplemental IDS w/accompanying papers

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

4-21-05

(Date)

Valerie L. Phillips

(Typed or Printed Name of Person Mailing Correspondence)

Valerie L. Phillips

(Signature of Person Mailing Correspondence)



1FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Giblin et al.

Intl. Serial No.: 10/508,761

Group Art Unit: 1615

Intl. File Date: September 22, 2004

Examiner: To Be Assigned

For: (2-((2-Alkoxy)-Phenyl)-Cyclopent-1-Enyl) Aromatic Carbo and Heterocyclic Acid and Derivatives

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed: 13-60

☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

(1) a final action under § 1.113 or

(2) a notice of allowance under § 1.311, whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.


Respectfully Submitted,



Lorie Ann Morgan

Registration No. 38,181

Date: *21 Apr 2005*
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8222
Facsimile: (919) 483-7988

EPO/PTO-1449 INFORMATION DISCLOSURE STATEMENT 	SERIAL NO.	10/508,761
	FILING DATE	September 22, 2004
	APPLICANT	Giblin et al.
	GROUP	1615
	EXAMINER	
ATTORNEY DOCKET NO.		P33027USW

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	6,495,149	Dec. 17, 2002	Scavone et al.			
	2	6,440,963	Aug. 27, 2002	Leonardi et al.			
	3	US 2002 045605	Apr. 18, 2002	Kargman et al.			
	4	6,136,839	Oct. 24, 2000	Isakson et al.			
	5	5,972,986	Oct. 26, 1999	Seibert et al.			
	6	5,840,746	Nov. 24, 1998	Ducharme et al.			
	7	5,663,180	Sept. 2, 1997	Reitz et al.			
	8	5,474,995	Dec. 12, 1995	Ducharme et al.			
	9	5,344,991	Sept. 6, 1994	Reitz et al.			
	10	5,420,287	May 30, 1995	Reitz, et al.			

Continue on page 2

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	13	EP 1264847	Dec. 11, 2002	EUROPE			Abstract only
	14	JP 2002363748	Dec. 18, 2002	JAPAN			Abstract only
	15	WO 02/099435	Dec. 12, 2002	WIPO			
	16	EP 1251126	Oct. 23, 2002	EUROPE			
	17	WO 01/081332	Nov. 1, 2001	WIPO			
	18	WO 00/53149	Sept. 14, 2000	WIPO			
	19	WO 00/47553	Aug. 17, 2000	WIPO			
	20	WO 99/58487	Nov. 19, 1999	WIPO			
	21	WO 99/17776	Apr. 15, 1999	WIPO			
	22	WO 98/55468	Dec. 10, 1998	WIPO			
	23	WO 98/16227	Apr. 23, 1998	WIPO			
	24	WO 97/16435	May 9, 1997	WIPO			
	25	WO 97/11701	Apr. 3, 1997	WIPO			
	26	WO 97/03667	Feb. 6, 1997	WIPO			
	27	WO 96/41645	Dec. 27, 1996	WIPO			
	28	WO 96/36623	Nov. 21, 1996	WIPO			
	29	WO 96/11676	Apr. 25, 1996	WIPO			
	30	WO 95/00501	Jan. 5, 1995	WIPO			
	31	WO 95/17393	June 29, 1995	WIPO			
	32	WO 95/05372	Feb. 23, 1995	WIPO			

Continue on page 2

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

58	Whitesell, J.K., et al. "Synthesis and Resolution of a New Chiral C2-Symmetric Bisphenol: Trans-1,2-Bis(2-Hydroxyphenyl)cyclopentane." Tetrahedron Letters, 1997, 38(15), pgs. 2589-2592.
59	Rathore, R., et al. "Efficient Hydrogenation of Sterically Hindered Olefins with Borane-Methyl Sulfide Complex." Journal of Organic Chemistry, 1996, 61(16), pgs. 5246-5256.
60	Malik, O.P., et al. "Studies on Cannabinoids: Part III. Synthesis of 9,10,11,11a-Tetrahydro-6H,8H-Pyrido(1,2-c) [1,3]benzoxazine." Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1976, 14B(12), pgs 975-978.

Continue on page 2

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

